Clinical Trials Browser

OTHER × Interventional × Gastrinoma × Clear all

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Glucagonoma, Insulinoma, Melanoma, Pheochromocytoma, Somatostatinoma, Carcinoma, Merkel Cell, Gastrinoma, Carcinoma, Islet Cell, Carcinoma, Medullary

NCT01525082 2024-02-06

Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors

Phase 2 Completed

20 enrolled 15 charts

EndocrineGastrointestinal

Glucagonoma, Insulinoma, Pancreatic Neoplasms, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell

NCT00227617 2023-05-22

Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors

Phase 2/3 Terminated

36 enrolled 14 charts

EndocrineNETThoracic

Vipoma, Glucagonoma, Insulinoma, Adenoma, Islet Cell, Lung Neoplasms, Neoplasms, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell, Neuroendocrine Tumors

NCT04915144 2023-02-21

177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs

Phase 2 Withdrawn

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Vipoma, Insulinoma, Gastrinoma, Neuroendocrine Tumors

NCT02259725 2021-12-15

Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors

Phase 2 Completed

3 enrolled 7 charts

Endocrine

Glucagonoma, Insulinoma, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell

NCT00730483 2017-08-25

Doxorubicin Beads in Treating Patients With Unresectable Liver Metastases From Neuroendocrine Tumors

Phase NA Terminated

13 enrolled 5 charts

Endocrine

Glucagonoma, Insulinoma, Adenoma, Islet Cell, Neoplasm Metastasis, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell

NCT02108782 2017-07-19

Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors

Phase 2 Withdrawn

Endocrine

Glucagonoma, Insulinoma, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell

NCT02273752 2017-02-03

Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer

Phase 2 Terminated

2 enrolled 5 charts

BreastEndocrineGenitourinaryOther

Breast Neoplasms, Carcinoma, Renal Cell, Glucagonoma, Insulinoma, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell, Mucositis

NCT00869050 2016-07-25

Capecitabine and Temozolomide for Neuroendocrine Cancers

Phase 2 Completed

41 enrolled 9 charts

EndocrineGastrointestinalNET

Carcinoid Tumor, Vipoma, Pancreatic Neoplasms, Pheochromocytoma, Somatostatinoma, Zollinger-Ellison Syndrome, Gastrinoma, Carcinoma, Medullary, Neuroendocrine Tumors

NCT00049023 2016-06-21

Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors

Phase 1 Completed

27 enrolled

CNSEndocrineSarcoma

Familial ependymoma, Insulinoma, Adenoma, Islet Cell, Medulloblastoma, Neuroblastoma, Pheochromocytoma, Sarcoma, Gastrinoma, Central Nervous System Neoplasms, Neuroectodermal Tumors, Primitive, Peripheral, Carcinoma, Islet Cell

NCT00416767 2016-05-30

Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery

Phase 2 Completed

20 enrolled

Endocrine

Vipoma, Glucagonoma, Insulinoma, Adenoma, Islet Cell, Neoplasms, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell

NCT00002947 2014-07-02

Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer

Phase 1 Terminated

35 enrolled

CNSDermatologicEndocrineGenitourinaryHead & NeckThoracic

Uveal Melanoma, Carcinoma, Renal Cell, Vipoma, Glucagonoma, Head and Neck Neoplasms, Insulinoma, Adenoma, Islet Cell, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasms, Pheochromocytoma, Somatostatinoma, Carcinoma, Merkel Cell, Gastrinoma, Central Nervous System Neoplasms, Carcinoma, Islet Cell, Carcinoma, Medullary, Esthesioneuroblastoma, Olfactory, Small Cell Lung Carcinoma

NCT00027638 2013-06-18

Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors

Phase 2 Completed

EndocrineThoracic

Vipoma, Glucagonoma, Insulinoma, Adenoma, Islet Cell, Lung Neoplasms, Neoplasms, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell

NCT00466856 2012-05-18

Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors

Phase 2 Terminated

10 enrolled

EndocrineHead & Neck

Vipoma, Glucagonoma, Head and Neck Neoplasms, Insulinoma, Adenoma, Islet Cell, Neoplasm Metastasis, Neoplasms, Pheochromocytoma, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell, Carcinoma, Medullary

Clinical Trials

Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors

Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors

Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors

177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs

Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors

Doxorubicin Beads in Treating Patients With Unresectable Liver Metastases From Neuroendocrine Tumors

Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors

Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer

Capecitabine and Temozolomide for Neuroendocrine Cancers

Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors

Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery

Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer

Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors

Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors